0001558370-23-002470.txt : 20230301 0001558370-23-002470.hdr.sgml : 20230301 20230301064018 ACCESSION NUMBER: 0001558370-23-002470 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230301 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 23689637 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 8-K 1 imgn-20230301x8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 1, 2023

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)



Massachusetts	0-17999	04-2726691
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (781) 895-0600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, $.01 par value	IMGN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 – RESULTS OF OPERATION AND FINANCIAL CONDITION

On March 1, 2023, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the Company’s financial results for the quarter and year ended December 31, 2022. The press release announcing financial results for the quarter and year ended December 31, 2022 is included as Exhibit 99.1 and incorporated herein by reference.

ITEM 9.01 Financial Statements and Exhibits.

(d): Exhibits

Exhibit No.		Exhibit

99.1		Press Release of ImmunoGen, Inc. dated March 1, 2023

104		Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ImmunoGen, Inc.
	(Registrant)

Date: March 1, 2023	/s/ Renee Lentini
	Renee Lentini
	Vice President - Finance, Chief Accounting Officer and Interim Chief Financial Officer

EX-99.1 2 imgn-20230301xex99d1.htm EX-99.1

Exhibit 99.1

ImmunoGen Reports Recent Progress and 2022 Financial Results

Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium

Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Q2 2023; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe

Encouraging Safety and Efficacy Data from Pivekimab Sunirine Triplet in AML Presented in Oral Session at ASH 2022; Clinical Collaboration with Gilead Announced to Evaluate Pivekimab with Magrolimab in Relapsed/Refractory AML

Announced a Global, Multi-Target License and Option Agreement of ImmunoGen's ADC Technology to Vertex; ImmunoGen to Receive a $15 Million Upfront Payment and is Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis

Appointments of Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs, and Daniel Char as Chief Legal Officer, Further Strengthen Management Team

Conference Call to be Held at 8:00 a.m. ET Today

Waltham, MA – March 1, 2023 – ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2022.

“We significantly advanced the business on multiple fronts over the last 12 months, most notably with the accelerated approval and launch of ELAHERE for patients with platinum-resistant ovarian cancer,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “We have seen broad and deep adoption of ELAHERE to date, with FRα testing, managed care coverage, and provider access all exceeding our expectations. Building upon this progress and in line with our goal of obtaining full approval for ELAHERE in the US and expanding into Europe, we will imminently reach the requisite number of PFS events in the confirmatory MIRASOL trial and expect to announce top-line data in the second quarter. In parallel, we are pursuing our broader development program in support of moving ELAHERE into platinum-sensitive disease and positioning ELAHERE as the combination agent of choice in ovarian cancer.”

Enyedy continued, “Turning to our second pivotal program, pivekimab sunirine, we presented promising findings from our triplet expansion cohorts in AML in an oral presentation at ASH in December, and continued enrollment in the pivotal CADENZA trial in frontline BPDCN with top-line data in de novo patients anticipated in 2024. We are also progressing our earlier-stage portfolio with the completion of dose escalation in the Phase 1 study of IMGC936, while also having dosed the first patient in our Phase 1 trial for IMGN151 in January. Combining our commitment to advance our pipeline of novel ADCs along with driving the commercial uptake of ELAHERE in the US, we are well positioned for another exciting and productive year.”

RECENT PROGRESS

ELAHERE (mirvetuximab soravtansine-gynx)

●

Received US Food and Drug Administration (FDA) accelerated approval of ELAHERE for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) on November 14, 2022.

●

Generated $2.6 million in net sales for the fourth quarter of 2022.

●

ELAHERE monotherapy and in combination with bevacizumab included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and compendium.

Clinical Pipeline

●

Published manuscript on the safety and efficacy of mirvetuximab in PROC in the SORAYA trial in the Journal of Clinical Oncology.

●

Published manuscript on the safety and efficacy of mirvetuximab in combination with bevacizumab in PROC in Gynecologic Oncology.

●

Completed enrollment in PICCOLO, a single-arm study of mirvetuximab monotherapy in FRα-high recurrent platinum-sensitive ovarian cancer (PSOC).

●

Presented data from expansion cohorts in the Phase 1b/2 study evaluating the pivekimab sunirine (pivekimab) triplet with Vidaza^® (azacitidine) and Venclexta^® (venetoclax) in relapsed/refractory (R/R) and initial data in frontline unfit acute myeloid leukemia (AML) in an oral presentation at the 2022 American Society of Hematology (ASH) Annual Meeting in December.

●

Progressed the pivotal Phase 2 CADENZA study of pivekimab sunirine (pivekimab) in frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN).

●

Completed dose escalation in the Phase 1 study of IMGC936 in multiple solid tumor types and initiated expansion cohorts in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

●

Enrolled the first patient in the Phase 1 study of IMGN151 in January 2023.

Corporate Development

●

Announced a global, multi-target license and option agreement granting Vertex Pharmaceuticals rights to conduct research using ImmunoGen's ADC technology to discover novel targeted conditioning agents for use with gene editing in exchange for a $15 million upfront payment and up to $337 million in potential option exercise fees, development and commercial milestones, and tiered royalties on a per target basis.

●

Announced a clinical collaboration with Gilead to evaluate the safety and anti-leukemia activity of pivekimab in combination with magrolimab, a potential first-in-class CD47 inhibitor, in patients with R/R CD123-positive AML.

●

Appointed Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs, and Daniel Char, JD, as Senior Vice President and Chief Legal Officer.

ANTICIPATED UPCOMING EVENTS

●

Report top-line data for MIRASOL in the second quarter of 2023.

●

Submit the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ELAHERE in FRα-high PROC in the second half of 2023 to support potential approval and launch.

●

Submit the supplemental Biologics License Application (sBLA) to the FDA in the second half of 2023 to support the conversion of the accelerated approval of ELAHERE to a full approval.

●

Our partner, Huadong Medicine, to submit the biologics license application (BLA) to the National Medical Products Administration (NMPA) of China for ELAHERE in FRα-high PROC in the second half of 2023 to support potential approval and launch.

●

Present efficacy data from the SORAYA trial by sequence of treatment and final overall survival analysis at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in March.

●

Report on the primary endpoint for PICCOLO before the end of 2023.

●

Complete enrollment of the efficacy evaluable cohort of de novo BPDCN patients in the pivotal phase 2 CADENZA study by the end of 2023.

●

Initiate the combination cohort of pivekimab with magrolimab in R/R AML in collaboration with Gilead in the second half of 2023.

●

Report dose escalation data in Phase 1 trial of IMGC936 and initial experience in expansion cohorts in the second quarter of 2023.

FINANCIAL RESULTS

Total revenues were $41.2 million for the quarter ended December 31, 2022 compared to $28.0 million for the quarter ended December 31, 2021, and $108.8 million for the year ended December 31, 2022 compared to $69.9 million for the year ended December 31, 2021. The increase in the quarter ended December 31, 2022 was primarily driven by one-time milestone payments achieved pursuant to the Company’s license and collaboration agreements with Huadong Medicine and Viridian Therapeutics. In addition to greater partner milestones achieved, the increase for the current year was driven by one-time license fees received pursuant to agreements executed with Eli Lilly and Magenta Therapeutics in 2022, as well as greater amortization in 2022 of the $40.0 million upfront fee previously received pursuant to the Company’s collaboration agreement with Huadong Medicine. The Company also recorded $2.6 million in net product revenue from sales of ELAHERE for the quarter and year ended December 31, 2022.

Research and development expenses rose to $58.5 million for the quarter ended December 31, 2022 compared to $49.0 million for the quarter ended December 31, 2021, and $213.4 million for the year ended December 31, 2022 compared to $151.1 million for the year ended December 31, 2021. The increases in both periods were driven by greater personnel and temporary staffing costs, external manufacturing costs, and third-party service fees, including medical affairs’ activities in support of the US commercial launch of ELAHERE in the fourth quarter of 2022, as well as greater clinical trial expenses. Additionally, research and development expenses for the year ended December 31, 2022 included $8.9 million of research costs to expand our ADC pipeline, inclusive of a one-time $7.5 million upfront fee paid to Oxford BioTherapeutics.

Selling, general and administrative expenses were $42.1 million for the quarter ended December 31, 2022 compared to $13.6 million for the quarter ended December 31, 2021, and $116.1 million for the year ended December 31, 2022 compared to $43.8 million for the year ended December 31, 2021. The increases in both periods were due primarily to building our commercial infrastructure and capabilities, including personnel-related costs and sales and marketing activities in support of the US launch of ELAHERE in the fourth quarter of 2022.

Net loss for the fourth quarter of 2022 was $59.0 million, or $0.23 per diluted share, compared to net loss of $37.2 million, or $0.17 per diluted share, for the fourth quarter of 2021. Net loss for the year ended December 31, 2022 was $222.9 million, or $0.88 per diluted share, compared to a net loss of $139.3 million, or $0.68 per diluted share, for the year ended December 31, 2021.

ImmunoGen had $275.1 million in cash and cash equivalents as of December 31, 2022, compared with $478.8 million as of December 31, 2021. Cash used in operations was $229.8 million for the year ended December 31, 2022 compared with $169.4 million for the year ended December 31, 2021. Capital expenditures were $1.4 million in each of the years ended December 31, 2022 and 2021.

During the quarter ended December 31, 2022, the Company sold 5.2 million shares of its common stock through its At-the-Market facility, generating net proceeds to the Company of $25.6 million.

FINANCIAL GUIDANCE

For 2023, ImmunoGen expects:

●

revenues, excluding product revenue from ELAHERE, between $30 million and $35 million; and

●

operating expenses between $310 million and $320 million.

ImmunoGen expects to provide ELAHERE product revenue guidance later this year.

Excluding anticipated ELAHERE and collaboration revenue, our level of cash and cash equivalents as of December 31, 2022, alone is not sufficient to meet our current operating plans through March 1, 2024. With the addition of forecasted ELAHERE product revenue and milestone payments under existing collaboration agreements, we expect these amounts combined with existing cash and cash equivalents will fund operations for more than 12 months from the date of this release. The Company intends to raise additional funds through equity, debt, or other financings.

CONFERENCE CALL INFORMATION

ImmunoGen will hold a conference call today at 8:00 a.m. ET to discuss these results. To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be

accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT ELAHERE™ (MIRVETUXIMAB SORAVTANSINE-GYNX)

ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells.

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Eye problems are common with ELAHERE and can be severe. ELAHERE also can cause severe or life-threatening inflammation of the lungs that may lead to death and patients may develop nerve problems called peripheral neuropathy during treatment. Please see full Prescribing Information, including Boxed Warning, and Medication Guide for ELAHERE.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Vidaza^®, and Venclexta^® are registered trademarks of their respective owners. ELAHERE™ is a trademark of ImmunoGen, Inc.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These statements include, but are not limited to, ImmunoGen’s expectations related to: the Company’s revenues and operating expenses for 2023; the Company’s anticipated cash runway; the Company’s expectations regarding future financing activities; the occurrence, timing, and outcome of potential preclinical, clinical, and regulatory events related to, and the potential benefits of, the Company’s product candidates, including, but not limited to: the commercialization of ELAHERE, the potential of ELAHERE to become the combination agent of choice, and the potential full approval of ELAHERE in the US and expansion to Europe; the timing and presentation of preclinical and clinical data on the Company’s product candidates, including data from the MIRASOL trial, data from the CADENZA trial, data from the SORAYA trial, and data from the Phase 1 trial of IMGC936; and the Company’s business and product development strategies. Various factors could cause ImmunoGen’s actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company’s preclinical and clinical development processes; the results of the ongoing MIRASOL trial may fail to support full approval of ELAHERE and, if not, additional studies may be required; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes; the timing and outcome of the Company’s anticipated interactions with regulatory authorities; the risk that we may not be able to obtain adequate price and reimbursement for any approved products, including the potential for delays or additional difficulties for ELAHERE in light of the FDA granting accelerated approval; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen’s industry and business; and other factors as set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2023 and other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

INVESTOR RELATIONS CONTACT

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com

MEDIA CONTACTS

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.com

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com


SELECTED FINANCIAL INFORMATION
(in thousands, except per share amounts)

CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

	December 31,		December 31,
	2022		2021
ASSETS

Cash and cash equivalents	$	275,138	$	478,750
Other assets		73,798		47,015

Total assets	$	348,936	$	525,765

LIABILITIES AND SHAREHOLDERS' EQUITY

Current portion of deferred revenue	$	13,856	$	44,351
Other current liabilities		108,002		56,594
Long-term portion of deferred revenue		36,355		47,717
Other long-term liabilities		34,897		51,517
Shareholders' equity		155,826		325,586

Total liabilities and shareholders' equity	$	348,936	$	525,765


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended				Year Ended
	December				December
	2022		2021		2022		2021

Revenues:
License and milestone fees	$	30,780	$	19,564	$	76,027	$	22,650
Non-cash royalty revenue		7,724		8,040		29,261		46,808
Product revenue, net		2,554		-		2,554		-
Research and development support		109		388		940		398

Total revenues		41,167		27,992		108,782		69,856

Cost and operating expenses:
Cost of sales		176		-		176		-
Research and development		58,485		48,968		213,370		151,117
Selling, general and administrative		42,065		13,578		116,129		43,812

Total cost and operating expenses		100,726		62,546		329,675		194,929

Loss from operations		(59,559)		(34,554)		(220,893)		(125,073)

Non-cash interest expense on liability related to sale of future royalty & convertible bonds		(971)		(2,151)		(4,165)		(13,103)
Interest expense on convertible bonds		-		-		-		(47)
Other income (loss), net		2,740		(467)		3,347		(1,080)

Loss before income taxes	$	(57,790)	$	(37,172)	$	(221,711)	$	(139,303)
Income tax expense		1,218		-		1,218		-

Net Loss	$	(59,008)	$	(37,172)	$	(222,929)	$	(139,303)
Basic and diluted net loss per common share	$	(0.23)	$	(0.17)	$	(0.88)	$	(0.68)

Basic and diluted weighted average common shares outstanding		254,405		215,830		253,361		206,147

GRAPHIC 3 imgn-20230301xex99d1001.jpg GRAPHIC begin 644 imgn-20230301xex99d1001.jpg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imgn-20230301.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 imgn-20230301_def.xml EX-101.DEF EX-101.LAB 6 imgn-20230301_lab.xml EX-101.LAB EX-101.PRE 7 imgn-20230301_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 01, 2023
Cover [Abstract]
Document Type	8-K
Document Period End Date	Mar. 01, 2023
Securities Act File Number	0-17999
Entity Registrant Name	ImmunoGen, Inc.
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2726691
Entity Address, Address Line One	Massachusetts
Entity Address, State or Province	MA
Entity Address, City or Town	Waltham
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	895-0600
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	IMGN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0000855654
Amendment Flag	false

XML 9 R2.htm IDEA: XBRL DOCUMENT

N-2	Mar. 01, 2023
Cover [Abstract]
Entity Central Index Key	0000855654
Amendment Flag	false
Securities Act File Number	0-17999
Document Type	8-K
Entity Registrant Name	ImmunoGen, Inc.
Entity Address, Address Line One	Massachusetts
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	895-0600
Entity Emerging Growth Company	false

XML 10 imgn-20230301x8k_htm.xml IDEA: XBRL DOCUMENT 0000855654 2023-03-01 2023-03-01 0000855654 false 8-K 2023-03-01 ImmunoGen, Inc. Massachusetts MA 0-17999 04-2726691 Waltham MA 02451 781 895-0600 false false false false Common Stock, $.01 par value IMGN NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.immunogen.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 2 false false All Reports Book All Reports imgn-20230301x8k.htm imgn-20230301.xsd imgn-20230301_def.xml imgn-20230301_lab.xml imgn-20230301_pre.xml imgn-20230301xex99d1.htm http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "imgn-20230301x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "imgn-20230301_def.xml" ] }, "inline": { "local": [ "imgn-20230301x8k.htm" ] }, "labelLink": { "local": [ "imgn-20230301_lab.xml" ] }, "presentationLink": { "local": [ "imgn-20230301_pre.xml" ] }, "schema": { "local": [ "imgn-20230301.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.sec.gov/cef/2022/cef-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd" ] } }, "elementCount": 199, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "imgn", "nsuri": "http://www.immunogen.com/20230301", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "imgn-20230301x8k.htm", "contextRef": "Duration_3_1_2023_To_3_1_2023_3zH0qsR6cE6Egyj9la5ePA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "imgn-20230301x8k.htm", "contextRef": "Duration_3_1_2023_To_3_1_2023_3zH0qsR6cE6Egyj9la5ePA", "decimals": null, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "imgn-20230301x8k.htm", "contextRef": "Duration_3_1_2023_To_3_1_2023_3zH0qsR6cE6Egyj9la5ePA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityFileNumber", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995470 - Disclosure - N-2", "menuCat": "Notes", "order": "2", "role": "http://xbrl.sec.gov/cef/role/N2", "shortName": "N-2", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 0, "tag": { "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundFeesAndExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "localname": "AcquiredFundFeesAndExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AllRisksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "localname": "AllRisksMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AllSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Securities:" } } }, "localname": "AllSecuritiesMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AnnualCoverageReturnRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "localname": "AnnualCoverageReturnRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualDividendPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "localname": "AnnualDividendPayment", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentCurrent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "localname": "AnnualDividendPaymentCurrent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentInitial": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "localname": "AnnualDividendPaymentInitial", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "localname": "AnnualExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AnnualInterestRateCurrentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "localname": "AnnualInterestRateCurrentPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRateInitialPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "localname": "AnnualInterestRateInitialPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "localname": "AnnualInterestRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_BasisOfTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "localname": "BasisOfTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_BdcFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "localname": "BdcFileNumber", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "cef_BusinessDevelopmentCompanyFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "localname": "BusinessDevelopmentCompanyFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_CapitalStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "localname": "CapitalStockTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DistributionServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "localname": "DistributionServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DistributionsMayReducePrincipalTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "localname": "DistributionsMayReducePrincipalTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "localname": "DividendAndInterestExpensesOnShortSalesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendExpenseOnPreferredSharesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "localname": "DividendExpenseOnPreferredSharesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendReinvestmentAndCashPurchaseFees": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "localname": "DividendReinvestmentAndCashPurchaseFees", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_EffectsOfLeveragePurposeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "localname": "EffectsOfLeveragePurposeTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "localname": "EffectsOfLeverageTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "localname": "EffectsOfLeverageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "localname": "ExpenseExampleTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleYear01": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "localname": "ExpenseExampleYear01", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to10": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "localname": "ExpenseExampleYears1to10", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "localname": "ExpenseExampleYears1to3", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to5": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "localname": "ExpenseExampleYears1to5", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_FeeTableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "localname": "FeeTableAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_FinancialHighlightsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "localname": "FinancialHighlightsAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_GeneralDescriptionOfRegistrantAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "localname": "GeneralDescriptionOfRegistrantAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_HighestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "localname": "HighestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "localname": "HighestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "localname": "IncentiveAllocationMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMinimumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "localname": "IncentiveAllocationMinimumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "localname": "IncentiveAllocationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "localname": "IncentiveFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_InterestExpensesOnBorrowingsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "localname": "InterestExpensesOnBorrowingsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IntervalFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "localname": "IntervalFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "localname": "InvestmentObjectivesAndPracticesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LatestNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest NAV" } } }, "localname": "LatestNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LatestPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "localname": "LatestPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LatestSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Share Price" } } }, "localname": "LatestSharePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LoanServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "localname": "LoanServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "localname": "LongTermDebtPrincipal", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtStructuringTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "localname": "LongTermDebtStructuringTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "localname": "LongTermDebtTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "localname": "LongTermDebtTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LowestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "localname": "LowestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "localname": "LowestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ManagementFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "localname": "ManagementFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NetExpenseOverAssetsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "localname": "NetExpenseOverAssetsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NewCefOrBdcRegistrantFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "localname": "NewCefOrBdcRegistrantFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_NoPublicTradingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "localname": "NoPublicTradingTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_NoTradingHistoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "localname": "NoTradingHistoryTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherAnnualExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 1.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "localname": "OtherAnnualExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 2.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "localname": "OtherAnnualExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 3.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "localname": "OtherAnnualExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "localname": "OtherAnnualExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherAnnualExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "localname": "OtherAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "localname": "OtherExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherFeederFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "localname": "OtherFeederFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherMasterFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "localname": "OtherMasterFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "localname": "OtherSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityDescriptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "localname": "OtherSecurityDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "localname": "OtherSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 1.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "localname": "OtherTransactionExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 2.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "localname": "OtherTransactionExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 3.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "localname": "OtherTransactionExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "localname": "OtherTransactionExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherTransactionExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "localname": "OtherTransactionExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "localname": "OtherTransactionFeesBasisMaximum", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_OtherTransactionFeesBasisMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "localname": "OtherTransactionFeesBasisMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "localname": "OtherTransactionFeesBasisNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "localname": "OtherTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "localname": "OutstandingSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecurityAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "localname": "OutstandingSecurityAuthorizedShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "localname": "OutstandingSecurityHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityNotHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "localname": "OutstandingSecurityNotHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "localname": "OutstandingSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "localname": "PreferredStockRestrictionsArrearageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsOtherTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "localname": "PreferredStockRestrictionsOtherTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PrimaryShelfFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "localname": "PrimaryShelfFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_PrimaryShelfQualifiedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "localname": "PrimaryShelfQualifiedFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ProspectusLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "localname": "ProspectusLineItems", "nsuri": "http://xbrl.sec.gov/cef/2022", "xbrltype": "stringItemType" }, "cef_ProspectusTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "localname": "ProspectusTable", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_PurposeOfFeeTableNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "localname": "PurposeOfFeeTableNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RegisteredClosedEndFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "localname": "RegisteredClosedEndFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ReturnAtMinusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "localname": "ReturnAtMinusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtMinusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "localname": "ReturnAtMinusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "localname": "ReturnAtPlusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "localname": "ReturnAtPlusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtZeroPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "localname": "ReturnAtZeroPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "localname": "RightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "localname": "RiskAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_RiskFactorsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "localname": "RiskFactorsTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "localname": "RiskTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SalesLoadPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "localname": "SalesLoadPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_SecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security [Axis]" } } }, "localname": "SecurityAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_SecurityDividendsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "localname": "SecurityDividendsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "localname": "SecurityLiabilitiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiquidationRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "localname": "SecurityLiquidationRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityObligationsOfOwnershipTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "localname": "SecurityObligationsOfOwnershipTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "localname": "SecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityVotingRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "localname": "SecurityVotingRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "localname": "SeniorSecuritiesAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesCoveragePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "localname": "SeniorSecuritiesCoveragePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit" } } }, "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "localname": "SeniorSecuritiesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "localname": "SeniorSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePriceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "localname": "SharePriceTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePricesNotActualTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "localname": "SharePricesNotActualTransactionsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ShareholderTransactionExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "localname": "ShareholderTransactionExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_TotalAnnualExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "localname": "TotalAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_UnderwritersCompensationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "localname": "UnderwritersCompensationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WaiversAndReimbursementsOfFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "localname": "WaiversAndReimbursementsOfFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WarrantsOrRightsCalledAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "localname": "WarrantsOrRightsCalledAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_WarrantsOrRightsCalledPeriodDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "localname": "WarrantsOrRightsCalledPeriodDate", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "localname": "WarrantsOrRightsCalledTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_WarrantsOrRightsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "localname": "WarrantsOrRightsExercisePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "dei_AdditionalSecurities462b": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "localname": "AdditionalSecurities462b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AdditionalSecurities462bFileNumber": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "localname": "AdditionalSecurities462bFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_AdditionalSecuritiesEffective413b": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "localname": "AdditionalSecuritiesEffective413b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.", "label": "Approximate Date of Commencement of Proposed Sale to Public" } } }, "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateOrAsapItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r7", "r8" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_DelayedOrContinuousOffering": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "localname": "DelayedOrContinuousOffering", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DividendOrInterestReinvestmentPlanOnly": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "localname": "DividendOrInterestReinvestmentPlanOnly", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "submissionTypeItemType" }, "dei_EffectiveAfter60Days486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "localname": "EffectiveAfter60Days486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "localname": "EffectiveOnDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "localname": "EffectiveOnDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnSetDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "localname": "EffectiveOnSetDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnSetDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "localname": "EffectiveOnSetDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling462e": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "localname": "EffectiveUponFiling462e", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "localname": "EffectiveUponFiling486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveWhenDeclaredSection8c": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "localname": "EffectiveWhenDeclaredSection8c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInvCompanyType": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).", "label": "Entity Inv Company Type" } } }, "localname": "EntityInvCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "invCompanyType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "yesNoItemType" }, "dei_ExhibitsOnly462d": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "localname": "ExhibitsOnly462d", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ExhibitsOnly462dFileNumber": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "localname": "ExhibitsOnly462dFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActFileNumber": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "localname": "InvestmentCompanyActFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActRegistration": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "localname": "InvestmentCompanyActRegistration", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendment": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "localname": "InvestmentCompanyRegistrationAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "localname": "InvestmentCompanyRegistrationAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_NewEffectiveDateForPreviousFiling": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "localname": "NewEffectiveDateForPreviousFiling", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462c": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "localname": "NoSubstantiveChanges462c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462cFileNumber": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "localname": "NoSubstantiveChanges462cFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_PostEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "localname": "PostEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PostEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.", "label": "Post-Effective Amendment Number" } } }, "localname": "PostEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "localname": "PreEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.", "label": "Pre-Effective Amendment Number" } } }, "localname": "PreEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Form N-2", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form N-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form N-4", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form N-6", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form S-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Investment Company Act", "Number": "270", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "313", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "413", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r20": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r21": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r22": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r23": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "e", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r24": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r25": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r26": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r27": { "Name": "Securities Act", "Publisher": "SEC", "Section": "8", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Form F-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001558370-23-002470-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-002470-xbrl.zip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end